Press release
Pegfilgrastim Biosimilars Market Emerging Trends, Revenue, Industry Size, Share, Business Growth And Competitive Outlook To 2031: Mylan, Biocon, Pfizer, Sandoz
Pegfilgrastim Biosimilars Market
The regions covered in the pegfilgrastim biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. Among these regions, North America accounts for the largest pegfilgrastim biosimilars market share.
Request For A Sample Of The Pegfilgrastim Biosimilars Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=4015&type=smp
The pegfilgrastim biosimilars market consists of the sales of pegfilgrastim biosimilars and related services offered by the companies that develop and manufacture them. Pegfilgrastim is a version of filgrastim (Neupogen), used to increase the production of infection-fighting white blood cells for the treatment of cancer patients undergoing chemotherapy. Pegfilgrastim biosimilars find their applications in reducing infection for patients undergoing anticancer therapy.
Key competitors in the pegfilgrastim biosimilars market are Mylan, Biocon, Mundipharma, Pfizer, Sandoz, Coherus, Intas Pharmaceuticals and Fresenius Kabi.
The global pegfilgrastim biosimilars market size is expected to grow from $1.17 billion in 2021 to $1.28 billion in 2022 at a compound annual growth rate (CAGR) of 10%. The growth in the market is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The pegfilgrastim biosimilars market is expected to reach $1.92 billion in 2026 at a CAGR of 10.6%.
Need More For Your Business Growth? Directly Purchase The Report Here:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=4015
TBRC's report segments the global pegfilgrastim biosimilars market:
1) By Application: Chemotherapy Treatment, Transplantation, Others
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Mail-Order Pharmacies
Read Further On The Pegfilgrastim Biosimilars Market Here:
https://www.thebusinessresearchcompany.com/report/pegfilgrastim-biosimilar-global-market-report
The Table Of Contents Includes:
1. Executive Summary
2. Pegfilgrastim Biosimilars Market Characteristics
3. Pegfilgrastim Biosimilars Market Trends And Strategies
4. Impact Of COVID-19 On Pegfilgrastim Biosimilars
5. Pegfilgrastim Biosimilars Market Size And Growth
.....
28. Key Mergers And Acquisitions In The Pegfilgrastim Biosimilars Market
29. Pegfilgrastim Biosimilars Market Future Outlook And Potential Analysis
30. Appendix
Contact us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
And check out our Blog: http://blog.tbrc.info/
Interested To Know More About The Business Research Company?
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that excels in company, market, and consumer research. Located globally, it has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services, chemicals, and technology.
The World's Most Comprehensive Database
The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Pegfilgrastim Biosimilars Market Emerging Trends, Revenue, Industry Size, Share, Business Growth And Competitive Outlook To 2031: Mylan, Biocon, Pfizer, Sandoz here
News-ID: 2566344 • Views: …
More Releases from The Business research company
Key Players and Competitive Dynamics in the Fifth Generation (5G) Radio Access N …
The evolution of wireless technology continues to accelerate, with the fifth generation (5G) radio access network (RAN) market positioned for remarkable growth. As the demand for faster, more reliable connectivity intensifies, this sector promises to transform how networks are built and operated across various industries. Let's explore the expected market expansion, driving forces, key players, emerging trends, and segmentation within the 5G RAN landscape.
Projected Market Size and Growth Trajectory of…
Overview of Segmentation, Market Dynamics, and Competitive Landscape in the Exte …
The world of extended reality (XR) content distribution platforms is poised for remarkable expansion as new technologies and applications reshape how immersive experiences are delivered and consumed. With growing interest across multiple sectors, this market is set to evolve rapidly, presenting exciting opportunities and challenges ahead. Below, we explore the current market outlook, major players, emerging trends, and segmentation details shaping this dynamic industry.
Extended Reality (XR) Content Distribution Platforms Market…
Leading Companies Fueling Innovation and Growth in the Emergency Medical Service …
The emergency medical services (EMS) software market is set to experience significant growth in the coming years, driven by technological advancements and increasing demand for efficient emergency response solutions. This report delves into the market's size projections, key players, emerging trends, and detailed segment analysis, offering a comprehensive understanding of its future direction.
Projected Size and Growth Trajectory of the Emergency Medical Services Software Market
The EMS software market is…
In-Depth Examination of Segments, Industry Trends, and Key Players in the Edge O …
The edge orchestration market is on the brink of significant expansion as businesses increasingly adopt advanced technologies to manage distributed computing environments. With the growing need for efficient management of edge devices and data, this sector is expected to experience rapid development in the coming years. Let's explore the current market valuation, key players, emerging trends, and the main segments shaping the future of edge orchestration.
Projected Market Size and Growth…
More Releases for Pegfilgrastim
Pegfilgrastim Biosimilars Market to Reach USD 1.22M by 2035
Can Pegfilgrastim Biosimilars Redefine Supportive Cancer Care Worldwide?
Pegfilgrastim Biosimilars Market: Global Overview, Trends, and Future Outlook
The Pegfilgrastim Biosimilars Market is emerging as a critical component of modern oncology care, driven by the rising global burden of cancer-particularly leukaemia-and the need to reduce the cost of biologic therapies. Pegfilgrastim, a long-acting granulocyte colony-stimulating factor (G-CSF), plays a vital role in preventing chemotherapy-induced neutropenia, a potentially life-threatening complication that increases infection risk…
Global Neulasta (Pegfilgrastim) And Biosimilar Market Size by Application, Type, …
USA, New Jersey- According to Market Research Intellect, the global Neulasta (Pegfilgrastim) And Biosimilar market in the Internet, Communication and Technology category is projected to witness significant growth from 2025 to 2032. Market dynamics, technological advancements, and evolving consumer demand are expected to drive expansion during this period.
The market for pegfilgrastim and biosimilars is expanding significantly, mostly due to the rising use of chemotherapy-based cancer treatments. By promoting the formation…
Global Pegfilgrastim Market Expects 5.8% Growth Rate from 2021-2028 Amid Rising …
According to the latest report published by Dataintelo, the Global Pegfilgrastim Market is projected to expand at a compound annual growth rate (𝐂𝐀𝐆𝐑) of 5.8% during the period between 2021 and 2028. This significant expansion in the market is primarily driven by the escalating number of cancer cases worldwide and an intensified demand for pegfilgrastim biosimilars.
The report highlights that the evolving global scenario of cancer management and treatment is fostering…
Pegfilgrastim Biosimilar Market to Exhibit 10% CAGR through 2026
Chemotherapy and/or radiotherapy is used for the treatment of most cancers. However, chemotherapy and radiotherapy have a very common side effect called neutropenia, and pegfilgrastim is required for its treatment. A study conducted on patients who received chemotherapy in 2016-2017 to evaluate the occurrence of chemotherapy-induced febrile neutropenia (CIFN) showed that, out of 200 patients, 9.5% patients developed neutropenia.
Click HERE to Get Synopsis of the Report- https://www.factmr.com/report/1494/pegfilgrastim-biosimilar-market
Neutropenia patients are highly…
Global Pegfilgrastim Market Analysis Report 2019-2024
This report on Global Pegfilgrastim Market details about the market size, market growth rate and global forecast for the next five years i.e. 2024. The report is a complete analysis assessing the pricing trends, market consumption and sales forecasts. This study covers the competitive landscape by profiling the major market players. The vital information of the market is collected through authentic sources and reviewed by industry experts.
Pegfilgrastim is a PEGylated…
Pegfilgrastim Biosimilar Market: Industry Trends and Developments 2018-2028
Biosimilar is a medical product that is almost an identical copy of an existing drug manufactured by a different company. They require independent approval through clinical trials. The Biosimilar market is an expanding market. Approximately 30% of drugs sold globally are biopharma drugs. 40% of prescription drug spending in the US is on biologic drugs. Filgrastim is used as a medication for treating low levels of blood neutrophils caused by…
